The long-sought discovery of HER2 as an actionable and highly sensitive therapeutic target
was a major breakthrough for the treatment of highly aggressive HER2-positive breast …

Simple Summary Breast cancer is the most-commonly diagnosed malignant tumor in women
in the world, as well as the first cause of death from malignant tumors. The incidence of …

Breast cancer is the most common cancer diagnosed in females throughout the entire world,
and it is also the primary reason why people lose their lives due to malignant tumors. The …

Amplification and/or overexpression of ERBB2, the gene encoding HER2, can be found in
15–20% of invasive breast cancers and is associated with an aggressive phenotype and …

Pathological and genomic profiling have transformed breast cancer care by matching
patients to targeted treatments. However, tumors evolve and evade therapeutic interventions …

CDK4/6 inhibitors have shown a synergistic effect with anti-HER2 therapy in hormone
receptor (HR)-positive and HER2-positive breast cancer (BC). In this phase 2 study …

Simple Summary The RAS/RAF/MEK/ERK pathway is implicated in fundamental processes
frequently altered in tumors, such as cell proliferation and survival. In breast cancer, it is …

Abnormal alterations in human epidermal growth factor receptor 2 (HER2, neu, and erbB2)
are associated with the development of many tumors. It is currently a crucial treatment for …

In recent decades, there has been a significant amount of research into breast cancer, with
some important breakthroughs in the treatment of both primary and metastatic breast …

HER2 mutations drive the growth of a subset of breast cancers and are targeted with HER2
tyrosine kinase inhibitors (TKI) such as neratinib. However, acquired resistance is common …